{"transactions":[{"id":945701,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T23:52:50.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":17.52,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001963544-26-000002","document":"wk-form4_1767743566.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000196354426000002/wk-form4_1767743566.xml","form_type":"4"}},{"id":1014137,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-24T01:06:30.000Z","date":"2025-10-21","kind":"purchase","planned":false,"acquired":true,"shares":533617,"price":18.74,"value":9999982.58,"ownership":{"direct":false,"nature":"Akeso, Inc."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest."}],"balance_after":32057147,"source":{"system":"sec-edgar","filing":"0001963544-25-000004","document":"wk-form4_1761267986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000196354425000004/wk-form4_1761267986.xml","form_type":"4"}},{"id":1309729,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T00:24:29.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":5438,"price":9.18,"value":49920.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $49,900."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date."}],"balance_after":5438,"derivative":{"exercise_price":18.35,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":5438},"source":{"system":"sec-edgar","filing":"0001599298-25-000027","document":"wk-form4_1736209460.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000027/wk-form4_1736209460.xml","form_type":"4"}},{"id":1309728,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T00:24:29.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":18.35,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001599298-25-000027","document":"wk-form4_1736209460.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000027/wk-form4_1736209460.xml","form_type":"4"}},{"id":1642618,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T21:35:18.000Z","date":"2023-01-17","kind":"purchase","planned":false,"acquired":true,"shares":10000000,"price":2.51,"value":25100000.0,"ownership":{"direct":false,"nature":"Akeso, Inc."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"10,000,000 shares of the Issuer's Common Stock were issued on January 17, 2023 in connection with the Collaboration and License Agreement with Akeso, Inc.(\"Akeso\") pursuant to which the Issuer issued Akeso such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest."}],"balance_after":10000000,"source":{"system":"sec-edgar","filing":"0001999371-24-002333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000199937124002333/ownership.xml","form_type":"5"}},{"id":1642617,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T21:35:18.000Z","date":"2023-03-07","kind":"purchase","planned":false,"acquired":true,"shares":21523530,"price":1.05,"value":22599706.5,"ownership":{"direct":false,"nature":"Akeso, Inc."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"21,523,530 shares of the Issuer's Common Stock were acquired on March 7, 2023 through a rights offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest."}],"balance_after":21523530,"source":{"system":"sec-edgar","filing":"0001999371-24-002333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000199937124002333/ownership.xml","form_type":"5"}},{"id":1686964,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:19:53.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on January 2, 2025."}],"balance_after":235000,"derivative":{"exercise_price":2.64,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001599298-24-000008","document":"wk-form4_1704403182.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000008/wk-form4_1704403182.xml","form_type":"4"}},{"id":1686963,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69938,"kind":"person","name":"Xia Yu","position":1,"cik":"0001963544","reported_name":"Xia Yu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:19:53.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":2.64,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001599298-24-000008","document":"wk-form4_1704403182.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000008/wk-form4_1704403182.xml","form_type":"4"}}]}